Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA) is a Great Choice

Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.

This method discovered several great candidates for momentum-oriented investors, but today let’s focus in on Vanda Pharmaceuticals Inc. VNDA as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for VNDA’s status as a solid momentum stock below:

Longer Term Price Change for Vanda Pharmaceuticals

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. That is why looking at longer term price metrics—such as performance over the past three months or year-- and comparing these to an industry at large can be very useful.

Vanda Pharmaceuticals Inc. Price

Vanda Pharmaceuticals Inc. Price | Vanda Pharmaceuticals Inc. Quote

And in the case of VNDA, the results are quite impressive. The company has beaten out the industry at large over the past 12 weeks by a margin of 18.1% to a decline of 2.8% while it has also outperformed when looking at the past year, putting up a gain of 15%. Clearly, VNDA is riding a bit of a hot streak and is worth a closer look by investors.  

Fiscal Year EPS Estimate Change for VNDA

In addition to price performance, it is also important to take a look at earnings estimate changes for the full year. This can show if VNDA is poised to make a run based on fundamentals, or if the company is simply moving on speculation.

Over the past month, the full year earnings estimate for VNDA has risen by 36.9%. On its own this is impressive, but considers that it also beats the industry average of 0.0% too. The trend is undeniably in Vanda Pharmaceuticals’ favor right now, and it suggests that the momentum might be long lasting for this stock.  

VNDA Earnings Estimate Revisions Moving in the Right Direction

While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with VNDA as of late too.

Over the past two months, two earnings estimates have gone higher compared to none lower for the full year, while we are also seeing that two estimates have moved upwards with no downward revision for the next year time frame too. These revisions have helped to boost the consensus estimate as two months ago VNDA was expected to post a loss of 65 cents per share for the full year, though today it looks to have a loss of 41 cents for the full year now, representing a solid increase which is something that should definitely be welcomed news to would-be investors.

Bottom Line

Given these factors, investors shouldn’t be surprised to note that we have VNDA as a security with a Zacks Rank #1 (Strong Buy) and a Momentum Score of ‘A’. You can see the complete list of today’s Zacks #1 Rank stocks here.

So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep VNDA on your short list as this looks be a stock that is very well-positioned to soar in the near term.

Zacks' 10-Minute Stock-Picking Secret

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.

Learn the secret >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Vanda Pharmaceuticals Inc. (VNDA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.